You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed or refractory haematological malignancies

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in

Completed
  • Relapsed or Refractory Haematological Malignancies Including
  • +10 more
  • Aachen, Germany
  • +11 more
Oct 21, 2021

Cancer, Malignancy, Refractory Cancer Trial in Singapore (Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ?d T

Not yet recruiting
  • Cancer
  • +3 more
  • Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
  • Singapore, Singapore
    National University Hospital
Mar 20, 2022

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Relapsed/Refractory B-cell Malignancies Trial (AC676)

Not yet recruiting
  • Relapsed/Refractory B-cell Malignancies
  • (no location specified)
Mar 27, 2023

Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

Not yet recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 27, 2023

Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)

Not yet recruiting
  • Relapsed/Refractory Aggressive B-Cell Malignancies
  • ONCT-808
  • Bridging Therapy
  • (no location specified)
Jan 19, 2023

Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)

Not yet recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • (no location specified)
Aug 4, 2023

Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

Not yet recruiting
  • Relapsed/Refractory Waldenstrom Macroglobulinemia
  • +3 more
  • Brexucabtagene Autoleucel
  • +2 more
  • (no location specified)
Sep 8, 2022

Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement

Recruiting
  • Lymphoma
  • +4 more
  • Vysis LSI MYC Break Apart Rearrangement Probe Kit
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Adult Relapsed/Refractory B-cell Hematologic Malignancies Trial in Beijing (CD19-CAR-NK)

Recruiting
  • Adult Relapsed/Refractory B-cell Hematologic Malignancies
  • CD19-CAR-NK
  • Beijing, Beijing, China
    The Fifth Medical Center of Chinese People's Liberation Army (PL
Dec 1, 2022

Relapsed Lymphoid Malignancies, Refractory Lymphoid Malignancies Trial in Bentleigh (CN1, 0.5mg/kg and CN401, 400mg, CN1, 1mg/kg

Terminated
  • Relapsed Lymphoid Malignancies
  • Refractory Lymphoid Malignancies
  • CN1, 0.5mg/kg and CN401, 400mg
  • +4 more
  • Bentleigh, Victoria, Australia
    Monash Health - Monash Medical Centre
Oct 20, 2022

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 22, 2023

Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 20, 2023

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 16, 2023

Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial

Not yet recruiting
  • Aggressive B-Cell Non-Hodgkin's Lymphoma
  • +4 more
  • (no location specified)
Dec 16, 2022

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Dec 13, 2022

Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Jun 8, 2023

Relapsed or Refractory B-cell Hematologic Malignancies Trial in Beijing, Nanjing (HEC89736)

Active, not recruiting
  • Relapsed or Refractory B-cell Hematologic Malignancies
  • Beijing, Beijing, China
  • +1 more
May 5, 2022

Haematological Malignancy Trial in Parkville (Nivolumab Injection)

Active, not recruiting
  • Haematological Malignancy
  • Nivolumab Injection
  • Parkville, Victoria, Australia
    Royal Melbourne Hospital
Sep 21, 2021

B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)

Not yet recruiting
  • B-cell Lymphoma
  • +7 more
  • CTX112
  • (no location specified)
Dec 12, 2022

T-ALL, Lymphoma, T-Cell Trial in Wuhan (SENL101)

Recruiting
  • T-ALL
  • Lymphoma, T-Cell
  • SENL101
  • Wuhan, Hubei, China
    Tongji Hospital
May 29, 2022